August 19, 2026
The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.
On July 30, 2026, GC Biopharma Corporation initiated a voluntary market withdrawal for three lots of Alyglo® (immune globulin intravenous, human-stwk) 10% Liquid. The withdrawal was initiated as a precautionary measure due to the potential for an increased rate of allergic hypersensitivity reactions associated with specific lots. Hypersensitivity reactions are a known risk with immune globulin products. Alyglo is FDA-approved for replacement therapy in adults with primary humoral immunodeficiency (PI). To read more about the withdrawal notice, see here.
Last updated: August 19, 2026